Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

被引：0

作者：

Tomoki Naoe

Akiko Saito

Nahoko Hosono

Senji Kasahara

Hideharu Muto

Kaoru Hatano

Mizuki Ogura

Taro Masunari

Masatsugu Tanaka

Kensuke Usuki

Yuichi Ishikawa

Koji Ando

Yukio Kondo

Yusuke Takagi

Satoru Takada

Maho Ishikawa

Ilseung Choi

Akihiro Sano

Hirokazu Nagai

机构：

[1] National Hospital Organization Nagoya Medical Center,Clinical Research Center

[2] National Hospital Organization Nagoya Medical Center,Clinical Research Center

[3] National Hospital Organization Headquarters,Department of Hematology and Oncology

[4] University of Fukui,Department of Hematology

[5] Gifu Municipal Hospital,Department of Blood Transfusion

[6] Tokyo Metropolitan Otsuka Hospital,Department of Hematology

[7] Jichi Medical University Hospital,Department of Hematology

[8] Japanese Red Cross Medical Center,Department of Hematology/Infectious Diseases

[9] Chugoku Central Hospital,Department of Hematology

[10] Kanagawa Cancer Center,Department of Hematology

[11] NTT Medical Center Tokyo,Department Hematology and Oncology

[12] Nagoya University Graduate School of Medicine,Department of Hematology

[13] Nagasaki University Hospital,Department of Hematology

[14] Toyama Prefectural Central Hospital,Department of Hematology

[15] Ogaki Municipal Hospital,Department of Hemato

[16] Leukemia Research Center,Oncology

[17] Saiseikai Maebashi Hospital,Department of Hematology and Cell Therapy

[18] Saitama Medical University International Medical Center,Department of Hematology

[19] National Hospital Organization Kyushu Cancer Center,undefined

[20] National Hospital Organization Nagoya Medical Center,undefined

来源：

Cancer Immunology, Immunotherapy | 2023年 / 72卷

关键词：

Acute myeloid leukemia (AML); Immunotherapy; Peptide vaccine; WT1; Biomarker;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We previously conducted a randomized phase II trial of OCV-501, a WT1 peptide presented by helper T cells, in elderly AML (acute myeloid leukemia) patients in first remission, indicating no difference in 2-year disease-free survival (DSF) between the OCV-501 and placebo groups. Here, we analyzed 5-year outcome and biomarkers. Five-year DFS was 36.0% in the OCV-501 group (N = 52) and 33.7% in the placebo group (N = 53), with no significant difference (p = 0.74). The peripheral WT1 mRNA levels were marginally suppressed in the OCV-501 group compared with the placebo group. Enhanced anti-OCV-501 IgG response by the 25th week was an independent favorable prognostic factor. Anti-OCV-501 IFNγ responses were less frequent than the IgG reactions. These findings suggest that host immunoreactivity has a significant impact on the prognosis of AML and that further improvement of the WT1 peptide vaccine is needed.

引用

页码：2865 / 2871

页数：6

共 51 条

[1] Klepin HD(2014)Acute myeloid leukemia and myelodysplastic syndromes in older adults J Clin Oncol 32 2541-2552
[2] Rao AV(2012)Acute myeloid leukemia in older adults Int J Hematol 96 186-193
[3] Pardee TS(2007)Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized acute leukemia French association (ALFA) 9803 trial Blood 109 5129-5135
[4] Yanada M(2011)Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60–70 years with acute myelogenous leukemia in first remission Biol Blood Marrow Transplant 17 1796-1803
[5] Naoe T(2023)Moving toward individualized target-based therapies in acute myeloid leukemia Ann Oncol 34 141-151
[6] Gardin C(2010)WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy Jpn J Clin Oncol 40 377-387
[7] Turlure P(2018)Advances in immunotherapy for acute myeloid leukemia Future Oncol 14 963-978
[8] Fagot T(2022)Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers (Basel) 14 2994-293
[9] Farag SS(2007)Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes J Immunother 30 282-863
[10] Maharry K(2017)A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia Cancer Immunol Immunother 66 851-1430

← 1 2 3 4 5 6 →